{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["82"],"submitter":["Sandhu G"],"pubmed_abstract":["Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clini"],"journal":["EClinicalMedicine"],"pagination":["103161"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12034076"],"repository":["biostudies-literature"],"pubmed_title":["Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice."],"pmcid":["PMC12034076"],"pubmed_authors":["Shingleton J","Mirkov S","Scuderi C","Ward RL","Malyszko J","Sprangers B","Stein BN","Kurkard C","Michael M","O'Neill N","Lucas C","Kelly A","Johnson DW","Boddy AV","Kichenadasse G","Kliman DS","Bagnis C","Morris E","Karapetis C","Ibrahim K","Roberts DM","Siderov J","Adattini J","Tey A","Wong R","Flynn A","Liauw W","Pollock CA","Webber K","Mallett AJ","Routledge DJ","Shortt J","Armstrong Gordon E","Hamilton B","McCaughan G","Chambers P","Kerr KA","Wichart J","Sandhu G","ADDIKD Working Group"],"additional_accession":[]},"is_claimable":false,"name":"Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.","description":"Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clini","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-08T03:10:51.281Z","creation":"2025-07-08T03:10:51.281Z"},"accession":"S-EPMC12034076","cross_references":{"pubmed":["40290844"],"doi":["10.1016/j.eclinm.2025.103161"]}}